10 new names found | Market-wide Finviz scan (mid-cap+ $2B+, 30%+ above SMA200, above SMA50) returned 100 candidates. 87 were already tracked. 13 were new — 10 passed yfinance validation with full golden cross confirmation.

The March 31 monster-scan found 104 monsters with energy and commodities dominating every tier. This discovery run asked the follow-on question: what else is running that we're not even watching? The answer: a scattered but coherent group that spans three themes we've been underweighting — specialty biotech, infrastructure energy storage, and satellite/comms.

The most interesting finds are COGT (+710% 1Y, rare disease biotech holding up in a broken market) and NKTR (+772% 1Y, a former collapsed biotech that has quietly rebuilt into a genuine multi-year monster). Both passed every filter cold — no prior tracking, no watchlist home, just algorithmic breakouts confirmed by golden crosses. KYMR (+278% 1Y) rounds out a biotech triad, all using different mechanisms (COGT: receptor kinase inhibition; KYMR: targeted protein degradation; NKTR: immunology/drug delivery). Three biotech names making the monster screen simultaneously in a risk-off market is a signal worth noting.

NXT (Nextracker, +203% 1Y) is the solar tracking standout — a relatively new public company that builds the mechanical systems rotating solar panels to track the sun, a pure infrastructure-cycle play benefiting from the massive utility-scale solar buildout underway. ENS (EnerSys, +115% 1Y) is the industrial battery angle — grid-scale and data center UPS storage demand is structurally growing, and ENS has the enterprise relationships to capture it.

AGRO (+91% 3M, +39% 1Y) is an agricultural commodities operator (Adecoagro, South American farming) that has gone parabolic on the food/ag tariff repricing thesis — it's the most direct pure-play farmland stock accessible from US markets and deserves a macro-commodities slot. CE (Celanese, +57% 3M) is the specialty chemicals name — makes acetyl chemicals and engineered materials — and while it's been out of favor for years, tariff-driven supply chain reshoring is sending demand its way.

GSAT (Globalstar, +253% 1Y, +41% SMA200) is the satellite communications outlier — Apple's continued use of Globalstar for emergency SOS and direct-to-device iPhone features gives it a recurring revenue anchor that the market is now pricing more seriously. NOK (Nokia, +34% SMA200) is the quietest name here: a slow-moving telecom equipment company that has been upgrading its product mix toward private 5G and data center networking, catching a bid from the infrastructure buildout wave.

GRDN (Guardian Pharmacy Services, +35% SMA200, +76% 1Y) is a specialty/long-term care pharmacy services company — less flashy than the others but with steady compounding momentum and no obvious catalyst headwinds.

COGT ($38.65, RSI 59, +58% above SMA200): Cogent Biosciences. Rare disease biotech targeting KIT/PDGFRA mutations. The 1-year 710% run is extraordinary and it's consolidating — not collapsing. RSI 59 with a golden cross means it's digesting the run rather than reversing. In a market where tech is broken and energy is peaking, a rare-disease biotech with strong mechanism science and this kind of momentum is a genuine standout. Watch for a pullback to the $34-36 range.

NKTR ($71.95, RSI 55, +54% above SMA200): Nektar Therapeutics. One of the great biotech resurrection stories — this stock was at $2 in 2023 and is now a multi-year compounder after pipeline validation for NKTR-358 (IL-2 pathway, autoimmune). The 772% 1Y return is the second-best on this list. RSI 55 and right at SMA20 after a 3M +70% run. The digest here looks healthy. This is the most underrated name in this batch — a pharma-turned-compounder that institutional money is quietly building.

NXT ($118.38, RSI 52, +37% above SMA200): Nextracker. IPO'd in 2023, makes solar tracker systems for utility-scale installations. With the US solar buildout accelerating and tariff-driven reshoring, NXT is a picks-and-shovels play on American energy infrastructure. +203% 1Y and still in strong-up trend. RSI 52 after a pullback from highs — constructive entry setup. Add to ev-clean-energy watch.

KYMR ($83.33, RSI 55, +33% above SMA200): Kymera Therapeutics. Targeted protein degradation (TPD) platform — a next-generation drug discovery approach that the large pharma companies are paying serious attention to. 3M change is modest (+7%) but the 1Y return of +278% tells the story. The recent 30D pullback (-7.5%) is a reset, not a reversal. Worth watching as a biotech with genuine science differentiation.

ENS ($172.62, RSI 55, +33% above SMA200): EnerSys. Industrial battery and energy storage systems. Data center UPS demand, grid storage, and the defense market (batteries for military systems) are all growing. This is a non-sexy but increasingly essential infrastructure name. +115% 1Y, RSI neutral, healthy trend.

GSAT ($65.82, RSI 57, +41% above SMA200): Globalstar. The Apple relationship (iPhone emergency SOS, direct-to-device messaging) creates predictable revenue that the market previously ignored. +253% 1Y. The 3M gain is modest (+7.8%) which suggests the big run has already happened — tracking for a re-entry setup rather than chasing here.

CE ($66.22, RSI 68, +38% above SMA200): Celanese. Specialty acetyl chemicals and engineered materials. Been in decline for years — this is a genuine turnaround that's accelerating on tariff tailwinds and cost cuts. RSI 68 and +56.7% in 3M suggests it's moving fast; don't chase above $70, wait for the first pullback.

AGRO ($15.12, RSI 72, +71% above SMA200): Already overbought. The 90%+ 3M move on South American agriculture stocks is a tariff play that may have already run. Watch for RSI to cool to 50-55 range before considering entry.

GRDN ($37.40, RSI 62, +35% above SMA200): Guardian Pharmacy Services. Solid compounder in long-term care pharmacy. Lower volatility, steady uptrend. Not urgent — add to monitor list for next pullback.

NOK ($7.97, RSI 51, +34% above SMA200): Nokia is slow-moving telecom equipment. The 5G and private network upgrade cycle is real but the stock moves in years, not months. RSI neutral, consolidating near SMA20 — it's in the watchlist now but not an active trade candidate today.

Five watchlists received new members:

• biotech-scan: COGT, KYMR, NKTR
• ev-clean-energy: NXT, ENS
• macro-commodities: AGRO, CE
• space: GSAT
• healthcare-scan: GRDN
• ai-infrastructure: NOK

This discovery run confirms the March 31 monster-scan picture with additional texture. The market has bifurcated into:

1. Energy/commodities (running) — already well-tracked, peaking in momentum
2. Biotech (quietly strengthening) — COGT, NKTR, KYMR represent a biotech cohort breaking out while the rest of the market corrects. This is sector rotation, not noise.
3. Infrastructure/industrial (steady) — NXT, ENS, ENS represent the physical economy buildout that is less correlated to AI sentiment and tariff risk than pure-tech names

The absence of new AI/semiconductor/cloud names from this scan is striking. Finviz returned zero new tech/AI names that weren't already tracked. The new monster universe is dominated by hard assets, biology, and physical infrastructure — exactly the rotation that the March full scan flagged as the dominant theme of Q1 2026.

Next monster-discover: suggested weekly or when a new sector theme needs coverage audit